Премия Ласкера — Дебейки за клинические медицинские исследования (англ.Lasker-DeBakey Clinical Medical Research Award) — одна из четырёх ежегодных премий, присуждаемых Фондом Альберта и Мэри Ласкеров[1]. Награда Ласкера-Дебейки присуждается врачам, ведущим клиническую практику за выдающуюся работу в области понимания, диагностики, профилактики и лечение болезней[2]. Эта награда была переименована в 2008 году в честь американского кардиохирурга Майкла Э. Дебейки[3]. Ранее она называлась «Премия Альберта Ласкера за клинические медицинские исследования» (англ.Albert Lasker Clinical Medical Research Award). Денежное содержание премии — 250 тысяч долларов[2].
For the discovery of the RH factor as a cause of hemolytic disease of the newborn and of severe hemolysis arising from incompatible blood transfusions.
For contributions to our knowledge of influenza, and the development of a vaccine effective against Types A and B, successfully used during World War II.
For contributions to cardiovascular research and his advancement of the concept that experimental atherosclerosis is basically a metabolic disease that is preventable and reversible.
For contributions to the understanding, diagnosis, and treatment of rickettsial diseases, including the demonstration of chloramphenicol as a cure for typhoid fever and scrub typhus.
For his brilliant leadership and professional accomplishments, which were responsible in a large measure for inaugurating a new era in cardiovascular surgery.
For original use of aminopterin and methotrexate in the control of acute childhood leukemia, and for his constant leadership in the search for chemical agents against cancer.
For pioneering contributions to the pathogenesis and treatment of severe immunodeficiency diseases, including the first successful allogeneic bone marrow transplants.
For conceptual and technical contributions to total hip joint replacement, which opened new horizons of research and treatment in arthritis and crippling joint diseases.
For pioneering contributions to the understanding of hereditary diseases, the development of effective genetic counseling procedures, and initiation of possible treatment by replacement of missing enzymes.
For clarifying the molecular basis and diagnosis of certain hereditary lysosomal storage disorders that may cause growth abnormalities, mental retardation, blindness, deafness and death.
For combining the techniques of cardiac catheterization and coronary artery cinematography, thus inaugurating the modern era of diagnosis and treatment of coronary artery disease.
For landmark clinical trials of lithium as therapy and prophylaxis for manic depressive illness, initiating a revolution in the treatment of mental disease.
For the understanding and demonstration that low-dose vitamin A supplementation in millions of third world children can prevent death from infectious diseases as well as blindness.
For incisive studies in patient-oriented research that paved the way for identifying genetic alterations that cause cancer in humans and that allow for cancer diagnosis in patients at the molecular level.
For developing an innovative approach to drug design based on protein structure and using it to create the ACE inhibitors, powerful oral agents for the treatment of high blood pressure, heart failure, and diabetic kidney disease.
«За открытие вируса гепатита C и разработку методов анализа в крови, который снизил риск заболевания гепатитом С до практически нуля по сравнению с 30 % в 1970-х годах»
For the development of renal hemodialysis, which changed kidney failure from a fatal to a treatable disease, prolonging the useful lives of millions of patients.
For revolutionizing the surgical removal of cataracts, turning a 10-day hospital stay with high morbidity into an outpatient procedure with minimal complications.
«За развитие когнитивной терапии, которая трансформировала понимание и лечение многих психических расстройств, включая депрессию, суицидальное поведение, генерализованную тревогу, приступы паники, и расстройств пищевого поведения.»
«За открытия статинов — препаратов с замечательными свойством снижения уровня LDL-холестерина, которые свершили революцию в профилактике и лечении ишемической болезни сердца.»
For the discovery of VEGF as a major mediator of angiogenesis and the development of an effective anti-VEGF therapy for wet macular degeneration, a leading cause of blindness in the elderly.
For the development of deep brain stimulation of the subthalamic nucleus, a surgical technique that reduces tremors and restores motor function in patients with advanced Parkinson’s disease.
For development of a system to study the replication of the virus that causes hepatitis C and for use of this system to revolutionize the treatment of this chronic, often lethal disease.
For technological advances that enabled development of HPV vaccines for prevention of cervical cancer and other tumors caused by human papillomaviruses
For the discovery and development of propofol, a chemical whose rapid action and freedom from residual effects have made it the most widely used agent for induction of anesthesia in patients throughout the world.
For their invention of Herceptin, the first monoclonal antibody that blocks a cancer-causing protein, and for its development as a life-saving therapy for women with breast cancer
For the discovery of a new therapeutic technology based on the modification of messenger RNA—enabling rapid development of highly effective Covid-19 vaccines
For the invention of optical coherence tomography, a technology that revolutionized ophthalmology—allowing rapid detection of diseases of the retina that impair vision
